Discover investment opportunities in Genetic Editing Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Genetic Editing Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Genetic Editing Stocks using our Smart AI Filter.
7 stocks found for "Genetic Editing Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
2.51 | ±100.0% | -1.1 | 0.00% | |||
1.92 | ±68.6% | -1.9 | 0.00% | |||
1.06 | ±44.4% | -272.1 | 0.00% | |||
1.34 | ±55.5% | -10.4 | 0.00% | |||
0.37 | ±22.9% | 21.1 | 0.52% | |||
0.30 | ±26.0% | 12.1 | 0.66% | |||
0.36 | ±26.9% | 24.5 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How does CRISPR Therapeutics (CRSP) stand out in the gene editing industry?
A: CRISPR Therapeutics is a leader in the gene-editing space due to its pioneering CRISPR-Cas9 technology. Its strategic collaborations and diverse pipeline targeting sickle cell disease and other genetic disorders enhance its industry position. However, regulatory and competitive challenges remain.
Q: Does Editas Medicine (EDIT) offer potential for growth investors?
A: Editas Medicine is considered a growth opportunity due to its focus on a broad range of gene therapies, including eye disorders and hematological diseases. However, uncertainty in clinical trial outcomes and regulatory approvals may impact growth potential.
Q: What are the ESG considerations for investing in Intellia Therapeutics (NTLA)?
A: Intellia Therapeutics is involved in cutting-edge genetic research, which presents ethical and social implications. Investors should consider the company's commitment to addressing potential societal impacts of gene editing and its transparency in clinical processes.
Q: Why might Beam Therapeutics (BEAM) be appealing to investors interested in innovation?
A: Beam Therapeutics' unique base editing technology represents a significant innovation within the gene editing field, potentially offering more precision and fewer off-target effects compared to CRISPR. This innovation may attract investors seeking cutting-edge biotechnology.
Q: What dividend potential does Sangamo Therapeutics (SGMO) offer?
A: Sangamo Therapeutics currently does not focus on dividends, as it reinvests earnings into R&D for genetic therapies. Investors seeking income should note the company's strategic priority on innovation rather than income distribution.
Q: How might economic cycles impact the performance of DermTech (DMTK)?
A: As a company focused on precision dermatology, DermTech's performance is largely driven by healthcare demand, which tends to be less cyclical. However, broader economic downturns could indirectly affect funding and consumer spending on elective treatments.